ArticleThe Journal of experimental medicine2026
Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2-deficient environments.
Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- γδ T cells and cancer.The Journal of clinical investigation · 2026Review
- Follow the "DOTs": Vδ1+ γδ T cells as effectors of cancer immunotherapy.The Journal of experimental medicine · 2026Review
- Multifaceted mechanisms of unconventional T cells in ischemia-reperfusion injury.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Regulatory T (Treg) cells are potent immunosuppressors of conventional αβ T cells in the tumor microenvironment, but how they may affect innate-like γδ T cells remains poorly understood. Here, we show that induced Treg depletion in mice selectively unleashes IFNγ-producing γδ T cells, which are required for tumor control in an orthotopic breast cancer model. Treg cells outcompete IFNγ+ γδ T cells for IL-2 due to increased expression of the high-affinity IL-2 receptor, thereby limiting the proliferation and effector functions of IFNγ+ γδ T cells. Consistently, in vivo neutralization of IL-2 alongside Treg depletion abrogates the induction of IFNγ+ γδ T cell responses, whereas administration of an IL-2Rβγc agonist circumvents Treg-mediated suppression and enhances tumor control. Finally, Treg cells also inhibit endogenous and expanded human γδ T-cells, which can be rescued by IL-2Rβγc agonism to enhance therapeutic responses in xenografted mice. Thus, bypassing Treg-mediated suppression may improve the outcome of γδ T cell-based immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.